https://www.selleckchem.com/
[This corrects the article DOI 10.18632/oncotarget.16892.]. Copyright © 2019 Zhang et al.VEGF-mediated tumor angiogenesis is a validated clinical target in many cancers, but modest efficacy and rapid development of resistance are major challenges of VEGF-targeted therapies. To establish a molecular signature of this resistance in ovarian cancer, we developed preclinical tumor models of adaptive resistance to chronic anti-VEGF treatment. We performed RNA-seq analysis and reverse-phase protein array to compare changes in gene and protein expressions in stroma
Gefällt mir
Kommentar
Teilen
